Updated pediatric hypertriglyceridemia guidance says triglyceride thresholds below 400 mg/dL mainly signal ASCVD risk, while levels above about 885 mg/dL raise pancreatitis risk. Lifestyle changes remain first-line treatment, and pediatric-specific evidence for drug therapy is still limited.
A phase 3 clinical trial has launched for pridopidine as a potential ALS treatment, while AI research identified 18 FDA-approved drugs that may extend survival. Separate studies found a promising three-drug combination for sporadic ALS using new cell models.
A major meta-analysis of 19 randomized trials involving 123,940 participants found that only six side effects are actually caused by statins, challenging long-standing concerns about the drugs' safety profile.
A randomized trial found that men with prostate cancer treated with the GnRH agonist leuprolide experienced significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix, suggesting a biological mechanism for cardiovascular risk differences between ADT drug pathways.
A phase three clinical trial shows enlicitide, an oral monoclonal antibody, reduced LDL cholesterol by 60% compared to placebo in 2,909 patients with or at risk of atherosclerosis over 24 weeks.
GLP-1 drugs for weight loss and diabetes are driving up health insurance premiums by about 30 percent, while consumer advocates petition for generic authorization citing unjustifiably high prices and strained federal budgets.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06134635 |
Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke |
NOT_YET_RECRUITING | |
| NCT03971019 |
Survival Benefits of Statins in Breast Cancer Patients |
UNKNOWN | PHASE3 |
| NCT03936361 |
Statins In Intracerbral Hemorrhage |
RECRUITING | PHASE3 |
| NCT03933293 |
A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH |
COMPLETED | PHASE2 |
| NCT03770702 |
Statins and ARBs on Rheumatoid Activity |
RECRUITING | PHASE3 |
| NCT02890992 |
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia |
COMPLETED | PHASE2 |
| NCT02642159 |
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) |
COMPLETED | PHASE4 |
| NCT01972178 |
Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia |
TERMINATED | PHASE2 |
| NCT01738542 |
Safety and Efficacy Study of Bosentan for Intermittent Claudication in Peripheral Arterial Disease |
COMPLETED | NA |
| NCT00968383 |
Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment |
TERMINATED | NA |
